Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. reports developments tied to its clinical-stage oncology pipeline, led by Plinabulin, an immune-modulating cancer therapy studied in non-small cell lung cancer and other indications. Recurring updates cover DUBLIN-3 data analyses, Plinabulin combinations with docetaxel, checkpoint inhibitors and antibody-drug conjugates, and presentations at oncology and immuno-oncology medical meetings.
Company news also includes periodic financial results, annual-report announcements, capital and corporate updates, and disclosures related to BeyondSpring’s equity interest in SEED Therapeutics and molecular glue degrader programs. These updates connect the company’s research activity, clinical-development strategy and financing actions with its public-company reporting cycle.
BeyondSpring (NASDAQ: BYSI) announced positive topline results from the PROTECTIVE-2 Phase 3 trial, evaluating Plinabulin in combination with Neulasta against Neulasta alone. The primary endpoint of reducing Grade 4 neutropenia was met (p0.01), along with key secondary endpoints for the duration of severe neutropenia (p<0.05). The trial showed that the combination offers early protection during the first chemotherapy cycle, potentially addressing a significant unmet medical need in cancer care. A conference call will provide further insights.
BeyondSpring (NASDAQ: BYSI) announced promising results from the PROTECTIVE-2 Phase 2 trial, showcasing its lead asset Plinabulin in combination with Neulasta. The study revealed a 72% reduction in chemotherapy dose adjustments, with only 6.3% of patients needing dose reduction compared to 22.7% in the Neulasta-only group. Additionally, no patients downgraded their chemotherapy regimen in the Plinabulin group, potentially leading to better long-term survival outcomes. The improvements address the critical issue of Grade 4 neutropenia prevalent during high-risk chemotherapy.
BeyondSpring (NASDAQ: BYSI) announced that its Phase 3 Dublin-3 clinical trial for Plinabulin in non-small cell lung cancer (NSCLC) has received a favorable recommendation from the Data & Safety Monitoring Board (DSMB) after reviewing data from over 500 patients. The trial aims to evaluate the efficacy of Plinabulin combined with docetaxel compared to docetaxel alone in second- and third-line EGFR wild-type NSCLC patients. Previous Phase 2 results showed that this combination significantly extends overall survival while reducing severe neutropenia rates.
Summary not available.
Summary not available.
Summary not available.